PubRank

Research In Viral Eradication of HIV Reservoirs (RIVER)

Clinical Trial ID NCT02336074

PubWeight™ 3.93‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02336074

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999 21.24
2 Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006 14.01
3 Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012 7.76
4 Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012 6.29
5 Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012 5.52
6 Short-course antiretroviral therapy in primary HIV infection. N Engl J Med 2013 4.82
7 Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 1992 4.58
8 Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009 4.32
9 Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012 3.99
10 Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009 3.71
11 Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999 2.95
12 [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B 1978 2.92
13 Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. J Virol 2001 2.66
14 Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007 2.61
15 Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 2004 2.51
16 Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A 2012 2.27
17 Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection. PLoS One 2010 2.09
18 Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol 1998 2.06
19 Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012 1.94
20 Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011 1.92
21 Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection. J Infect Dis 2005 1.80
22 Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011 1.80
23 Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 2013 1.53
24 Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 2001 1.52
25 Absence of HIV-1 evolution in the gut-associated lymphoid tissue from patients on combination antiviral therapy initiated during primary infection. PLoS Pathog 2012 1.26
26 Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 2006 1.24
27 HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy. Antivir Ther 2012 1.23
28 Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. AIDS 2011 1.13
29 A CD46-binding chimpanzee adenovirus vector as a vaccine carrier. Mol Ther 2007 0.96
30 Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses. Clin Exp Immunol 2007 0.92
31 Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat. J Virol 2015 0.90
32 Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1? Retrovirology 2012 0.90
33 Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS 2011 0.88
34 Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One 2014 0.86
35 Ongoing Clinical Trials of Human Immunodeficiency Virus Latency-Reversing and Immunomodulatory Agents. Open Forum Infect Dis 2016 0.80
36 Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells. AIDS 2015 0.77
37 Combining HDAC inhibitors with oncolytic virotherapy for cancer therapy. Oncolytic Virother 2015 0.76
38 The therapeutic potential of epigenetic manipulation during infectious diseases. Pharmacol Ther 2016 0.75
Next 100